Apogee Therapeutics reported positive Phase 2 results for APG777, an anti-IL-13 antibody for atopic dermatitis, demonstrating a 71% reduction in disease severity over placebo and comparable efficacy to existing treatments like Dupixent. Notably, APG777 is designed for less frequent dosing, potentially offering a more convenient alternative. The company is planning Phase 3 studies, signaling a potential new treatment standard in inflammatory skin disease.